Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal woman (for at least 5 years) or men who are aged between 45 to 85~* Participant who has low bone mineral density~* Participant has anatomy suitable for dual-energy x-ray absorptiometry (DXA) of the lumber spine and hip~* Participant is ambulatory (can walk)~Exclusion Criteria:~* Participant has secondary osteoporosis or has a metabolic bone disorder other than osteoporosis or osteopenia~* Participant has received osteoporosis medications or other medications that affect bone~* Participant is already participating in another drug study

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): After an observation period of \~5 weeks, participants receive dose-matched placebo to odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 International Units (IU) vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium \<1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
- Odanacatib 10 mg (Type: EXPERIMENTAL): After an observation period of \~5 weeks, participants receive 10 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium \<1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
- Odanacatib 25 mg (Type: EXPERIMENTAL): After an observation period of \~5 weeks, participants receive 25 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium \<1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
- Odanacatib 50 mg (Type: PLACEBO_COMPARATOR): After an observation period of \~5 weeks, participants receive 50 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium \<1000 mg per day from dietary and other sources) throughout the observation and treatment periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).